Pdt Partners, LLC Alkermes Plc. Transaction History

Pdt Partners, LLC

$1.45 Billion
Q3 2025

A detailed history of Pdt Partners, LLC transactions in Alkermes Plc. stock. As of the latest transaction made, Pdt Partners, LLC holds 24,198 shares of ALKS stock, worth $702,709. This represents 0.05% of its overall portfolio holdings.

Number of Shares

24,198

Previous 91,610 73.59%

Holding current value

$702,709

Previous $2.62 Million 72.33%

% of portfolio

0.05%

Previous 0.17%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$26.13 - $30.46 $1.76 Million - $2.05 Million	-67,412 Reduced 73.59%	24,198 $725,000
Q2 2025 Aug 14, 2025	SELL	$26.59 - $32.65 $1.06 Million - $1.3 Million	-39,773 Reduced 30.27%	91,610 $2.62 Million
Q1 2025 May 15, 2025	BUY	$28.08 - $36.0 $770,402 - $987,696	27,436 Added 26.39%	131,383 $4.34 Million
Q4 2024 Feb 14, 2025	SELL	$25.7 - $31.46 $282 - $346	-11 Reduced 0.01%	103,947 $2.99 Million
Q3 2024 Nov 14, 2024	BUY	$23.01 - $28.55 $1.82 Million - $2.26 Million	79,158 Added 319.19%	103,958 $2.91 Million

Q2 2024 Aug 15, 2024	BUY	$23.21 - $27.24 $575,608 - $675,552	24,800 New	24,800 $597,000
Q3 2023 Nov 14, 2023	BUY	$27.17 - $31.97 $1.7 Million - $2 Million	62,507 Added 610.72%	72,742 $2.04 Million
Q2 2023 Aug 14, 2023	SELL	$28.34 - $33.63 $1.42 Million - $1.68 Million	-50,075 Reduced 83.03%	10,235 $320,000
Q1 2023 May 15, 2023	SELL	$25.31 - $29.02 $2.05 Million - $2.35 Million	-81,051 Reduced 57.34%	60,310 $1.7 Million
Q4 2022 Feb 14, 2023	BUY	$21.94 - $26.24 $251,476 - $300,762	11,462 Added 8.82%	141,361 $3.69 Million
Q3 2022 Nov 14, 2022	SELL	$22.0 - $31.87 $1.17 Million - $1.69 Million	-53,047 Reduced 29.0%	129,899 $2.9 Million
Q2 2022 Aug 15, 2022	BUY	$26.4 - $30.54 $377,757 - $436,996	14,309 Added 8.49%	182,946 $5.45 Million
Q1 2022 May 16, 2022	SELL	$23.07 - $27.99 $769,753 - $933,914	-33,366 Reduced 16.52%	168,637 $4.44 Million
Q4 2021 Feb 14, 2022	BUY	$21.47 - $32.08 $1.1 Million - $1.64 Million	51,203 Added 33.95%	202,003 $4.7 Million
Q3 2021 Nov 15, 2021	SELL	$23.37 - $32.13 $1.98 Million - $2.72 Million	-84,800 Reduced 35.99%	150,800 $4.65 Million
Q2 2021 Aug 16, 2021	BUY	$18.78 - $25.15 $877,777 - $1.18 Million	46,740 Added 24.75%	235,600 $5.78 Million
Q1 2021 May 17, 2021	BUY	$18.21 - $23.2 $455,832 - $580,742	25,032 Added 15.28%	188,860 $3.53 Million
Q4 2020 Feb 16, 2021	SELL	$15.39 - $22.1 $689,041 - $989,461	-44,772 Reduced 21.46%	163,828 $3.27 Million
Q3 2020 Nov 16, 2020	SELL	$16.16 - $20.66 $115,236 - $147,326	-7,131 Reduced 3.31%	208,600 $3.46 Million
Q2 2020 Aug 14, 2020	SELL	$13.31 - $19.41 $1.68 Million - $2.45 Million	-126,169 Reduced 36.9%	215,731 $4.19 Million
Q1 2020 May 15, 2020	BUY	$13.06 - $21.24 $1.42 Million - $2.31 Million	108,881 Added 46.73%	341,900 $4.93 Million
Q4 2019 Feb 14, 2020	BUY	$17.29 - $21.74 $402,286 - $505,824	23,267 Added 11.09%	233,019 $4.75 Million
Q3 2019 Nov 14, 2019	BUY	$19.51 - $24.28 $1.79 Million - $2.23 Million	91,652 Added 77.61%	209,752 $4.09 Million
Q2 2019 Aug 14, 2019	BUY	$21.47 - $37.33 $563,651 - $980,024	26,253 Added 28.58%	118,100 $2.66 Million
Q1 2019 May 15, 2019	SELL	$28.4 - $36.49 $1.18 Million - $1.52 Million	-41,653 Reduced 31.2%	91,847 $3.35 Million
Q4 2018 Feb 14, 2019	BUY	$27.94 - $44.61 $1.4 Million - $2.24 Million	50,231 Added 60.32%	133,500 $3.94 Million
Q3 2018 Nov 14, 2018	SELL	$38.6 - $46.12 $1.62 Million - $1.93 Million	-41,931 Reduced 33.49%	83,269 $3.53 Million
Q2 2018 Aug 14, 2018	BUY	$40.56 - $51.36 $5.08 Million - $6.43 Million	125,200 New	125,200 $5.15 Million

Others Institutions Holding ALKS

# of Institutions

400

Shares Held

176M

Call Options Held

901K

Put Options Held

400K

View Full List

About Alkermes plc.

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.77B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

More about ALKS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.

Account